Global Pulmonary Alveolar Proteinosis (PAP) Market: Industry Analysis & Outlook (2017-2025)

1
Industry Research by Koncept Analytics
Global Pulmonary Alveolar Proteinosis (PAP)
Market Industry Analysis Outlook
-----------------------------------------
(2017-2025)
November 2017
2
Executive Summary
Pulmonary alveolar proteinosis (PAP) is a rare
respiratory disease caused by the accumulation of
a surfactant (proteins and lipids) accumulated in
small air bags of the lung, called alveoli, which
interfere with breathing. PAP condition occurs in
6 individuals per million and is considered an
orphan disease. Pulmonary surfactant is produced
by the body in healthy people and patients with
PAP, which is a mixture of phospholipids and
synthesized proteins. These surfactants form cell
lines to prevent the collapse of the pulmonary
membranes by reducing the surface tension. This
pulmonary surfactant must be constantly replaced
to maintain the active and functional layer and
to prevent excessive layering. The exact reason
for the accumulation of excess surfactants is
unknown. This requires a signal and messenger
molecule called granulocyte-macrophage colony
stimulating factor (GM-CSF) to stimulate alveolar
macrophages to work properly and maintain a
normal level of surfactant in the cells. This
process of maintaining a stable state is known as
homeostasis and requires that GM-CSF stimulate
alveolar macrophages to remove excess
surfactant. Treatment of PAP depends on the form
of PAP and age of a patient with PAP and severity
of the disease. WLL is a standard treatment for
PAP and the only treatment which has shown
improved symptoms and oxygenation in patients.
Another treatment of PAP includes using
recombinant granulocyte colony stimulating factor
(GM-CSF) which is given by nose or with a
subcutaneous injection which is not approved yet.
The global PAP market is expected to show
significant growth after the introduction of the
molgradex drug in 2020. The growth of market will
mainly be driven by huge unmet demand, increasing
male population, rising middle-aged population
and increasing health expenditure. However, the
growth of the market will be hindered by the
absence of effective diagnostics and costly
drugs. The report Global Pulmonary Alveolar
Proteinosis (PAP) Market Industry Analysis
Outlook (2017-2025) analyzes the development of
this market, with focus on the US, Europe, and
Japan region. The major trends, growth drivers as
well as issues being faced by the market are
discussed in detail in this report. A key
upcoming player in the market i.e. Savara Inc. is
being profiled along with its key financials and
strategies for growth. The report contains a
comprehensive analysis of the global PAP market
along with the study of the regional markets.
3
Increasing PAP prevalence and health care
expenditure supported the growth of global PAP
market.
Global PAP Patient Prevalence Forecast (2017-2025)

• The global PAP prevalence is anticipated to reach
  thousand in year 2025, increasing from thousand
  patients in 2017, recording growth at a CAGR of
  for the period spanning 2017-2025.
• The addressable population for Molgradex is
  expected to reach thousand in 2025, increasing
  from .thousand, growing at a rate of for the
  period spanning 2017-2025.
• In 2020, the prevalence of PAP in Europe with .
  share of total prevalence, followed by the US and
  Japan with .. and .. shares respectively.

Global Molgradex Addressable Population Forecast
(2017-2025)
Global PAP Prevalence Forecast by Region (2020)
4
Strong RD efforts and launch of Molgradex drug
will drive growth of global PAP drug market
The US Patient on Molgradex Therapy Forecast
(2020-2025)

• The US patients on molgradex therapy is likely to
  reach thousand in 2025, increasing from
  .thousand in 2020, as the product is expected to
  be launched in the market in year 2020.
• In Europe, Molgradex revenue is anticipated to
  reach US.... million in 2025, increasing from
  US... million, growing at a CAGR of . for the
  period spanning 2020-2025.
• In Japan, the addressable population for
  Molgradex treatment is anticipated to reach in
  2025, increasing from in 2017, growing at a
  CAGR of for the period spanning 2017-2025.

Europe Molgradex Revenue Forecast (2020-2025)
Japan Molgradex Addressable Population Forecast
(2017-2025)
5
For Report Purchase Click Belowhttp//www.koncep
tanalytics.com/Researchreport/global-pulmonary-alv
eolar-proteinosis-pap-market-industry-analysis-out
look-2017-2025-26471.aspx
Disclaimer
Contact Us
This is a licensed product of Koncept Analytics.
You cannot reproduce, publish, distribute,
publicly display, sell or create other works from
this report or use them in any way for commercial
purpose without our prior permission. Further,
you cannot copy this material, by any means
(including electronic copies), for distribution
to others unless you have purchased the corporate
license of this report. We believe the sources
are reliable, but Koncept Analytics does not
warranty the accuracy or completeness of the
data. The data presented in the report is updated
at the publication date but is subject to change
at subsequent releases. All possible efforts have
been made to ensure accuracy of data. However,
investors should not completely rely on the
information given in this report and must make
decisions based on their own investment strategy,
risk management and capital adequacy.
Koncept Analytics CS-36, First Floor, Ansal
Plaza Vaishali, Ghaziabad, U.P. 201010 T
91-120-4130959 M 91-9871694789vikas_at_konceptana
lytics.com
www.konceptanalytics.com